Dr Charles Haworth
Role title/s:
- Consultant Respiratory Physician, Cambridge Centre for Lung Infection, Royal Papworth Hospital
- Clinical Trials Lead, Cambridge Centre for Lung Infection, Royal Papworth Hospital
- Affiliated Associate Professor, University of Cambridge
Email: charles.haworth@nhs.net
PA Name: Cate Bromley
PA Email: Catherine.Bromley1@nhs.net
Twitter: N/A
LinkedIn: N/A
Mastodon/other social media: N/A
Biography
“Charles Haworth is a Respiratory Consultant within the Cambridge Centre for Lung Infection at Royal Papworth Hospital and an Affiliated Associate Professor at the University of Cambridge. He is also a member of the Board of the European Cystic Fibrosis Society. His research involves evaluating novel therapeutic approaches in patients with bronchiectasis, cystic fibrosis and NTM related lung disease. He collaborates with Professor Andres Floto at the University of Cambridge on a variety of experimental medicine studies. He has been chief investigator of four international commercial clinical trial programmes and is a steering committee member of phase I/II/III medicinal trials currently being performed in the UK, Europe and North America. He has received research funding from EU FP7 (x2), NIHR (x3) and HDR UK grants. He is a member of the European Bronchiectasis Registry Steering Committee and Scientific Committee; he is a site Principal Investigator for the European Cystic Fibrosis Society Clinical Trials network; and is a member of the Scientific Advisory Board of the Cambridge NIHR Clinical Research Facility.”
Research Approach
Clinical trialist
Current projects
International Chief Investigator roles:
- Phase III pivotal trials evaluating the safety and efficacy of nebulised colistin in patients with bronchiectasis.
Current investigator-led studies:
- Inhaled acidified nitrite for the treatment of Mycobacterium abscessus-lung disease [in collaboration with Prof. Andres Floto and 30 Technology]
- Use of volatile organic compounds to assess pulmonary exacerbations in patients with cystic fibrosis [in collaboration with Prof. Andres Floto and Owlstone]
- Bedside radar in the early detection of pulmonary exacerbations in CF [in collaboration with Prof. Andres Floto and Circadia]
- Evaluation of high frequency chest wall oscillation in patients with bronchiectasis [in collaboration with Tactile Medical]
- Use of home monitoring and artificial intelligence to detect pulmonary exacerbations before they become clinically apparent in patients with bronchiectasis [in collaboration with Prof Andres Floto and Lucy Gale]
International Steering Committee roles:
- Zambon (phase III study of nebulised colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa)
- Insmed (phase III study of Brensocatib in patients with bronchiectasis)
- Vertex (inhaled mRNA / liposomal nano particle programme)
- AstraZeneca/EMBARC (phase III study of a monoclonal antibody in patients with bronchiectasis and Pseudomonas aeruginosa)
Industry links
- Consultancy for AstraZeneca, BiomX, Infex, Insmed, LifeArc, Pneumagen, 30 Technology, Vertex, Zambon
Selected Publications
- Haworth CS, et al. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. Lancet Resp Med. In press. [first author]
- Loebinger MR, et al. Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study. Eur Respir J. 2021 [senior author]
- Chalmers JD, Haworth CS, et al. Phase II trial of the DPP-1 inhibitor Brensocatib in bronchiectasis. New Engl J Med. 2020 [second author]
- Haworth CS, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. Lancet Respir Med. 2019 [first author]
- Haworth CS, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Resp Crit Care Med 2014 [first author]
Research collaborators
Professor Andres Floto, University of Cambridge
Professor James Chalmers, University of Dundee
Professor Adam Hill, University of Edinburgh
Professor Antony De Soyza, University of Newcastle
Professor Kevin Southern, University of Liverpool
